Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 clinical development. We evaluated the antiatherogenic potential of alirocumab in APOE*3Leiden.CETP mice. Mice receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Kühnast, Susan, van der Hoorn, José W. A., Pieterman, Elsbet J., van den Hoek, Anita M., Sasiela, William J., Gusarova, Viktoria, Peyman, Anusch, Schäfer, Hans-Ludwig, Schwahn, Uwe, Jukema, J. Wouter, Princen, Hans M. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Biochemistry and Molecular Biology 2014
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174003/
https://www.ncbi.nlm.nih.gov/pubmed/25139399
http://dx.doi.org/10.1194/jlr.M051326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174003/
https://www.ncbi.nlm.nih.gov/pubmed/25139399
http://dx.doi.org/10.1194/jlr.M051326

Ejemplares similares